2.18
-0.02(-0.91%)
Currency In USD
| Previous Close | 2.2 |
| Open | 2.22 |
| Day High | 2.24 |
| Day Low | 2.17 |
| 52-Week High | 5.2 |
| 52-Week Low | 2 |
| Volume | 414,125 |
| Average Volume | 946,090 |
| Market Cap | 231.77M |
| PE | -5.45 |
| EPS | -0.4 |
| Moving Average 50 Days | 2.4 |
| Moving Average 200 Days | 3.43 |
| Change | -0.02 |
If you invested $1000 in MaxCyte, Inc. (MXCT) since IPO date, it would be worth $128.24 as of July 01, 2025 at a share price of $2.18. Whereas If you bought $1000 worth of MaxCyte, Inc. (MXCT) shares 3 years ago, it would be worth $466.81 as of July 01, 2025 at a share price of $2.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
GlobeNewswire Inc.
Jun 11, 2025 6:00 AM GMT
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelinesROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT;
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire Inc.
Apr 10, 2025 6:00 AM GMT
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-ge
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
GlobeNewswire Inc.
Feb 12, 2025 7:00 AM GMT
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseasesROCKVILLE, Md